Lupus nephritis Medical Services in China

Lupus nephritis (LN) is a severe, immune-mediated kidney complication of systemic lupus erythematosus (SLE), characterized by inflammation and damage to the glomeruli, tubules, interstitium, and vasculature of the kidneys. It occurs when autoantibodies—particularly anti-double-stranded DNA (anti-dsDNA) and anti-nuclear antibodies—form immune complexes that deposit in renal tissues, triggering complement activation, leukocyte infiltration, and cytokine-driven inflammation. This cascade leads to progressive glomerular injury, proteinuria, hematuria, hypertension, and, if untreated, irreversible fibrosis and end-stage kidney disease. LN affects approximately 30–60% of SLE patients over their lifetime, with higher incidence among individuals diagnosed with SLE before age 40. Epidemiologically, LN disproportionately impacts women (female-to-male ratio ~9:1), particularly those of African, Hispanic, Asian, and Indigenous descent—populations exhibiting both higher SLE prevalence and more aggressive renal involvement. Key risk factors include genetic susceptibility (e.g., variants in IRF5, STAT4, HLA-DR2/DR3), early-onset SLE (<20 years), persistent high disease activity, serologic markers like low C3/C4 and elevated anti-dsDNA titers, and socioeconomic barriers to timely care. Beyond physical morbidity, LN significantly impairs quality of life: chronic fatigue, pain, cognitive dysfunction ('lupus fog'), anxiety and depression are common; treatment-related side effects—including corticosteroid-induced weight gain, osteoporosis, diabetes, and infection risk—further diminish functional capacity and psychosocial well-being. Patients often face work disability, reduced social participation, and caregiver dependency, especially during flares or dialysis-dependent stages. Early diagnosis via urine analysis (proteinuria >0.5 g/day, active sediment), serum creatinine, eGFR, and confirmatory renal biopsy (classified per ISN/RPS 2003 criteria) is critical. Without intervention, up to 10–30% of LN patients progress to end-stage kidney disease within 10 years. Modern management emphasizes immunosuppression tailored to histopathologic class (e.g., Class III/IV treated with mycophenolate mofetil or cyclophosphamide plus glucocorticoids; Class V with calcineurin inhibitors), alongside rigorous blood pressure control (target <120/80 mmHg), RAAS blockade, and lifestyle optimization. Emerging biologics—including belimumab (approved for active LN) and voclosporin (FDA-approved for active LN)—are reshaping therapeutic paradigms toward improved renal preservation and reduced steroid burden.

Lupus nephritis (LN) is a severe, immune-mediated glomerulonephritis occurring in 30–60% of patients with systemic lupus erythematosus (SLE). As a leading cause of morbidity and mortality in SLE, timely diagnosis—via renal biopsy with histopathologic classification (ISN/RPS 2018)—and risk-stratified management are essential. Treatment aims to induce remission, prevent relapse, preserve renal function, and minimize cumulative organ damage and treatment-related toxicity.

Conservative management forms the cornerstone of LN care and must be initiated concurrently with immunosuppressive therapy. Blood pressure control targets <120/80 mmHg using renin-angiotensin-aldosterone system inhibitors (RAASi), preferably angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), which confer dual antiproteinuric and renoprotective effects independent of blood pressure reduction. Strict proteinuria monitoring (urine protein-to-creatinine ratio, UPCR) is mandatory, with goal reduction to <0.5 g/g within 6–12 months. Patients require rigorous cardiovascular risk mitigation: lipid-lowering therapy (high-intensity statins if LDL-C ≥70 mg/dL), smoking cessation, weight optimization, and diabetes screening. Hydroxychloroquine is continued indefinitely at 5 mg/kg/day (ideal body weight), as it reduces flares, thrombotic events, and mortality. Sun protection, vaccination (inactivated influenza, pneumococcal, hepatitis B, COVID-19), and avoidance of nephrotoxic agents—including NSAIDs and iodinated contrast unless absolutely necessary—are non-negotiable components of conservative care.

Pharmacotherapy is stratified by histologic class and clinical severity. For Class III (focal) and IV (diffuse) LN—particularly IV-G(A) or IV-S(A)—induction therapy consists of mycophenolate mofetil (MMF) 2–3 g/day or intravenous cyclophosphamide (IV-CYC) per the Euro-Lupus regimen (500 mg every 2 weeks × 6 doses), both combined with glucocorticoids. MMF is preferred first-line due to superior safety profile, especially in reproductive-age women and non-Caucasian populations. Glucocorticoid regimens have evolved toward lower cumulative exposure: oral prednisone 0.5–0.75 mg/kg/day tapered over 24–26 weeks, often preceded by pulse methylprednisolone (500–1000 mg × 3 days) for severe presentations (e.g., rapidly progressive GN, nephrotic syndrome with AKI). For refractory or high-risk LN (e.g., Class IV with crescents, Class VI), biologics are increasingly integrated. Belimumab (10 mg/kg IV monthly or subcutaneous 200 mg weekly) is FDA- and EMA-approved as add-on therapy to standard-of-care, reducing renal flares and time to first flare. Voclosporin—a calcineurin inhibitor with enhanced pharmacokinetic predictability—was approved in 2021 for active LN when combined with MMF and low-dose steroids, demonstrating significantly higher complete renal response rates (40.8% vs. 22.5% at 52 weeks) in the AURORA trial. Rituximab remains off-label but is considered in steroid-resistant or MMF-intolerant cases, particularly with concomitant hematologic or neuropsychiatric involvement. Maintenance therapy follows successful induction: MMF 1–2 g/day or azathioprine 2 mg/kg/day for ≥3 years, with gradual steroid withdrawal. Therapeutic drug monitoring (e.g., mycophenolic acid levels) may optimize efficacy in non-responders.

Surgical intervention plays a highly limited role in LN. Renal biopsy—percutaneous ultrasound- or CT-guided—is diagnostic and prognostic but not therapeutic. Nephrectomy is contraindicated except in rare, catastrophic scenarios such as irreversible cortical necrosis with life-threatening complications (e.g., uncontrolled hypertension, malignant hypertension-induced encephalopathy, or massive hemorrhage), none of which represent standard indications. Dialysis initiation follows standard nephrology criteria (eGFR <15 mL/min/1.73m², uremic symptoms, refractory fluid/electrolyte imbalance); however, LN patients exhibit higher rates of renal recovery post-dialysis initiation compared to other etiologies—especially those with Class III/IV disease and preserved tubular function—underscoring the importance of aggressive immunosuppression even in acute kidney injury. Kidney transplantation is viable after ≥6 months of sustained extra-renal and renal remission (UPCR <500 mg/g, stable eGFR, no active serologic activity), with 5-year graft survival exceeding 85% in experienced centers. Recurrence of LN in the allograft occurs in ~5–10% of recipients and is managed with intensified immunosuppression, not surgical revision.

China offers distinct advantages in LN management, anchored in its integrated, high-volume, multidisciplinary nephrology infrastructure. Over 30 national LN referral centers—including Peking University First Hospital, West China Hospital, and Shanghai Renji Hospital—participate in standardized protocols aligned with KDIGO 2021 and Chinese Society of Nephrology (CSN) guidelines. These centers leverage AI-assisted histopathology interpretation, real-time electronic health record-based flare prediction algorithms, and centralized biorepositories linked to longitudinal outcomes databases. Traditional Chinese Medicine (TCM) adjuncts—such as Tripterygium wilfordii Hook F (TwHF) extract—are rigorously studied in randomized trials; meta-analyses confirm TwHF enhances complete renal response when added to MMF (RR 1.32, 95% CI 1.15–1.52) with manageable hepatotoxicity under monitoring. Moreover, China’s national drug pricing negotiations have reduced costs of biologics (e.g., belimumab price cut >40% since 2022) and generic MMF, improving adherence. Tele-nephrology networks now cover >85% of prefecture-level cities, enabling remote monitoring of proteinuria and medication titration, thereby reducing geographic disparities in care access.

Recovery and long-term follow-up demand structured patient engagement. Patients should undergo quarterly assessments including serum creatinine, eGFR, UPCR, complement C3/C4, anti-dsDNA titers, and urinalysis. Annual dual-energy X-ray absorptiometry (DEXA) scans screen for glucocorticoid-induced osteoporosis; calcium/vitamin D supplementation and bisphosphonates are initiated proactively. Mental health support is integral—depression and anxiety prevalence exceeds 40% in LN—and cognitive behavioral therapy (CBT) integration into nephrology clinics improves treatment adherence and quality of life. Pregnancy counseling must occur preconception: conception is advised only during sustained remission (>6 months), with close maternal-fetal surveillance and continuation of hydroxychloroquine, low-dose aspirin, and adjusted MMF (discontinued pre-pregnancy, replaced by azathioprine). Finally, patients are educated on early flare recognition—new onset edema, foamy urine, fatigue, arthralgia, or rising anti-dsDNA—prompting immediate contact with their nephrology team. With contemporary, individualized strategies, >75% of patients achieve complete renal response within 2 years, and 10-year patient survival exceeds 90% in tertiary centers adhering to evidence-based protocols.